Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview | 11 | 1 |
| Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Comparative Analysis | 12 | 1 |
| Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics under Development by Companies | 13 | 2 |
| Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Pipeline Products Glance | 15 | 4 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Unknown Stage Products | 18 | 1 |
| Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Products under Development by Companies | 19 | 2 |
| Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Companies Involved in Therapeutics Development | 21 | 26 |
| AnGes MG, Inc. | 21 | 1 |
| AstraZeneca Plc | 22 | 1 |
| Athera Biotechnologies AB | 23 | 1 |
| Athersys, Inc. | 24 | 1 |
| Bayer AG | 25 | 1 |
| Betagenon AB | 26 | 1 |
| BiogenCell Ltd. | 27 | 1 |
| CardioVascular BioTherapeutics, Inc. | 28 | 1 |
| Celgene Corporation | 29 | 1 |
| Diffusion Pharmaceuticals Inc | 30 | 1 |
| Hemostemix Ltd | 31 | 1 |
| ID Pharma Co., Ltd. | 32 | 1 |
| Juventas Therapeutics, Inc. | 33 | 1 |
| LipimetiX Development Inc | 34 | 1 |
| miRagen Therapeutics, Inc. | 35 | 1 |
| Nuo Therapeutics, Inc. | 36 | 1 |
| Proteon Therapeutics, Inc. | 37 | 1 |
| Recardio GmbH | 38 | 1 |
| Resverlogix Corp. | 39 | 1 |
| Sigma-Tau S.p.A. | 40 | 1 |
| Stemedica Cell Technologies, Inc. | 41 | 1 |
| Symic Biomedical, Inc. | 42 | 1 |
| Theravasc, Inc. | 43 | 1 |
| VESSL Therapeutics Ltd | 44 | 1 |
| ViroMed Co Ltd | 45 | 1 |
| Yuyu Pharma, Inc. | 46 | 1 |
| Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Assessment | 47 | 9 |
| Assessment by Monotherapy Products | 47 | 1 |
| Assessment by Target | 48 | 2 |
| Assessment by Mechanism of Action | 50 | 2 |
| Assessment by Route of Administration | 52 | 2 |
| Assessment by Molecule Type | 54 | 2 |
| Drug Profiles | 56 | 96 |
| ACP-01 Drug Profile | 56 | 3 |
| AEM-28 Drug Profile | 59 | 2 |
| ALD-301 Drug Profile | 61 | 2 |
| alprostadil Drug Profile | 63 | 1 |
| Annexin A-5 Drug Profile | 64 | 1 |
| apabetalone Drug Profile | 65 | 9 |
| BAY-1193397 Drug Profile | 74 | 1 |
| BC-1 Drug Profile | 75 | 1 |
| beperminogene perplasmid Drug Profile | 76 | 6 |
| CVBT-141C Drug Profile | 82 | 1 |
| DVC-10101 Drug Profile | 83 | 1 |
| ELS-140 Drug Profile | 84 | 1 |
| JVS-100 Drug Profile | 85 | 5 |
| levocarnitine propionate hydrochloride Drug Profile | 90 | 1 |
| MGN-6114 Drug Profile | 91 | 1 |
| MultiGeneAngio Drug Profile | 92 | 1 |
| O-304 Drug Profile | 93 | 2 |
| PC-mAb Drug Profile | 95 | 2 |
| PDA-002 Drug Profile | 97 | 1 |
| PF-05285401 Drug Profile | 98 | 10 |
| REC-03 Drug Profile | 108 | 1 |
| Rejuveinix Drug Profile | 109 | 1 |
| rivaroxaban Drug Profile | 110 | 14 |
| SB-030 Drug Profile | 124 | 2 |
| sodium nitrite SR Drug Profile | 126 | 2 |
| Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology Drug Profile | 128 | 6 |
| transcrocetinate sodium Drug Profile | 134 | 4 |
| TXA-127 Drug Profile | 138 | 3 |
| V-10 Drug Profile | 141 | 1 |
| VM-202 Drug Profile | 142 | 3 |
| vonapanitase Drug Profile | 145 | 4 |
| YY-984 Drug Profile | 149 | 1 |
| zibotentan Drug Profile | 150 | 2 |
| Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Dormant Projects | 152 | 4 |
| Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Discontinued Products | 156 | 1 |
| Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Product Development Milestones | 157 | 10 |
| Featured News &Press Releases | 157 | 1 |
| Oct 25, 2016: Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference | 157 | 1 |
| Oct 20, 2016: Dr. Jackie R. See M.D. Joins AngioSoma, Scientific Advisory Board | 157 | 1 |
| Oct 20, 2016: Proteon Therapeutics Appoints Paul Hastings Chairman of Its Board of Directors | 158 | 1 |
| Oct 11, 2016: AngioSoma Files 3 New Patent Applications on Liprostin | 158 | 1 |
| Oct 03, 2016: Hemostemix Announces it has been Granted two Additional Patents in the US and in Canada | 159 | 1 |
| Sep 29, 2016: Low levels of endogenous anti-PC identified as a novel risk factor for vein bypass graft failure and cardiovascular complications in PAD patients | 159 | 1 |
| Sep 28, 2016: Athera presents positive First-in-Patient data with their new antibody against immunovascular disease at ESVS | 160 | 1 |
| Aug 11, 2016: Athera Biotechnologies completes First-in-Patient Study with New Antibody Against Immunovascular Disease | 160 | 1 |
| May 24, 2016: Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis &Transplant Association Congress (ERA-EDTA) | 161 | 1 |
| Apr 13, 2016: Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease | 162 | 1 |
| Feb 04, 2016: Juventas Therapeutics Enrolls First Patient in Phase 2 Gene Therapy Clinical Trial for Treatment of Advanced Peripheral Artery Disease | 162 | 1 |
| Oct 12, 2015: Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015 | 163 | 1 |
| Aug 13, 2015: Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease | 164 | 1 |
| Feb 02, 2015: The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor | 165 | 1 |
| Jan 08, 2015: Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease | 165 | 2 |
| Appendix | 167 | 2 |
| Methodology | 167 | 1 |
| Coverage | 167 | 1 |
| Secondary Research | 167 | 1 |
| Primary Research | 167 | 1 |
| Expert Panel Validation | 167 | 1 |
| Contact Us | 167 | 1 |
| Disclaimer | 168 | 1 |